Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk stratification and prognostic factors in patients with unresectable undifferentiated carcinoma of the pancreas.
Imaoka H, Ikeda M, Maehara K, Umemoto K, Ozaka M, Kobayashi S, Terashima T, Inoue H, Sakaguchi C, Tsuji K, Shioji K, Okamura K, Tsujimoto A, Nakamura I, Shirakawa H, Furukawa M, Ueno M, Morizane C, Furuse J. Imaoka H, et al. Among authors: umemoto k. Pancreatology. 2021 Jun;21(4):738-745. doi: 10.1016/j.pan.2021.02.008. Epub 2021 Feb 14. Pancreatology. 2021. PMID: 33602645
Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer.
Kobayashi S, Suzuki M, Ueno M, Maruki Y, Okano N, Todaka A, Ozaka M, Tsuji K, Shioji K, Doi K, Kojima Y, Tsumura H, Tanaka K, Higuchi H, Kawabe K, Imaoka H, Yamashita T, Miwa H, Nagano H, Arima S, Hayashi H, Naganuma A, Yamaguchi H, Hisano T, Umemoto K, Ishii S, Nakashima K, Suzuki R, Kitano Y, Misumi T, Furuse J, Ishii H. Kobayashi S, et al. Among authors: umemoto k. Oncologist. 2022 Oct 1;27(10):e774-e782. doi: 10.1093/oncolo/oyac157. Oncologist. 2022. PMID: 35946841 Free PMC article.
Efficacy of chemotherapy for patients with metastatic or recurrent pancreatic adenosquamous carcinoma: A multicenter retrospective analysis.
Yoshida Y, Kobayashi S, Ueno M, Morizane C, Tsuji K, Maruki Y, Mori K, Watanabe K, Ohba A, Furuta M, Todaka A, Tsujimoto A, Ozaka M, Okano N, Yane K, Umemoto K, Kawamoto Y, Terashima T, Tsumura H, Doi K, Shioji K, Asagi A, Kojima Y, Suzuki E, Toshiyama R, Furukawa M, Naganuma A, Suzuki R, Miwa H, Ikeda M, Furuse J. Yoshida Y, et al. Among authors: umemoto k. Pancreatology. 2022 Dec;22(8):1159-1166. doi: 10.1016/j.pan.2022.09.236. Epub 2022 Sep 8. Pancreatology. 2022. PMID: 36150984
Current status of the cost burden of first-line systemic treatment for patients with advanced hepatocellular carcinoma in Japan, 2021-22.
Imaoka H, Sasaki K, Machida R, Nagano H, Satoi S, Ikeda M, Kobayashi S, Yamashita T, Okusaka T, Ido A, Hatano E, Miwa H, Ueno M, Nakao K, Shimizu S, Kuramochi H, Sakamori R, Tsumura H, Okano N, Shioji K, Shirakawa H, Akutsu N, Tsuji K, Ishii H, Umemoto K, Asagi A, Ueno M; JCOG Hepatobiliary and Pancreatic Oncology Group. Imaoka H, et al. Among authors: umemoto k. Jpn J Clin Oncol. 2024 Oct 3;54(10):1071-1077. doi: 10.1093/jjco/hyae048. Jpn J Clin Oncol. 2024. PMID: 38843879
206 results